Clinical Chemistry

QUALITY CONTROL

TERMS TO REMEMBER:

- **Quality:** a feature/characteristic of a product which meets the expected criteria of a consumer (customer).
- **Control:** a solution that resembles a human sample that is used for QC purposes only
- **Standard:** a colorless solution with **known** concentration of substances used for calibration
- **Specificity:** defined as the ability of a method to measure the analyte of interest ONLY.
- Sensitivity: defined as the ability of a method to measure analytes even at its lowest concentration
- Accuracy: nearness of measured value to that of the target value
- **Precision:** nearness of measured values to each other
- **Diagnostic specificity:** defined as the ability of a method to detect a population of individuals **absent of a disease process**
- **Diagnostic sensitivity:** defined as the ability of a method to detect a population of individuals having the **presence of disease**
- Intralab QC (internal QC): control samples are run simultaneously with a patient to ensure reliability of methods and result. Used for daily monitoring of accuracy and precision of method used. Detects random and systematic errors.
- Interlab QC (external QC): laboratories are given samples with unknown concentrations for them to test and results are compared with other laboratories thus maintaining "long-term accuracy" to methods utilized.
 - Results difference of **greater than 2SD** indicates disagreement with other lab included.
- Mean: average of a set of values (mean = $\Sigma x/n$). Measures central tendency.
- Median: midpoint of a set of values
- Mode: the most frequent among all values/data
- Range: Simplest expression of spread or distribution

• **Standard Deviation:** it is defined as the measure of dispersion of values to that of the mean. Most frequent used measure of variation.

$$\circ \quad SD = \sqrt{\frac{\Sigma(\mathbf{x} - \mathbf{mean})^2}{n-1}}$$

• Coefficient of variation: mean expression in percentile. Index of precision

$$\circ \quad CV = \frac{SD}{mean} x \ \mathbf{100}$$

- Variance: square of SD. V=SD²
- **T-test:** this is used to assess if there is a statistical difference between the **means** of 2 groups of data
- F-test: this is used to assess if there is a statistical difference between the SD of 2 groups of data
- Shewhart Levey-Jennings Chart: most widely used QC chart
- Trend: six or more consecutive values that either increase or decrease gradually (will cross the mean) main cause: reagent deterioration
- Shift: six or more consecutive values that are distributed on one side or other side of the mean (does NOT cross the mean) main cause: improper instrument calibration

| WESTGARD RULES | | | |
|-------------------------|----------------------------|---|--|
| TYPE OF ERROR | RULES | SOURCES OF ERROR | |
| RANDOM | 1 _{2s} (warning | By chance errors: mislabeling, pipetting | |
| - Tests for imprecision | rule), 1 _{3s} and | error, fluctuations in temperature & | |
| | R _{4s} | voltage | |
| SYSTEMATIC | 2_{2s} , 4_{1s} and | Improper calibration, reagent | |
| - Tests for inaccuracy | 10x | deterioration, contaminated solutions, | |
| | | instability of both samples and solutions | |

- **Delta check:** used to check if there are significant differences between present set of values to that of past values on the sample of same individual.
- Six Sigma: a way of improving product processing to eliminate defects

$A = -logT = \frac{\log 1}{T}$

INSTRUMENTATION

DEFINITION OF TERMS:

- Energy: entity that this transmitted by electromagnetic waves
- Wavelength: defined as the distance between two successive peaks
- Nanometer: unit expression of wavelength
- Frequency: number of waves that passes a point of observation per one unit of time



SPECTROPHOTOMETRY

- Measures transmitted light in a colored solution
- Measurement is based upon Beer-Lambert-Bouguer Law (Beer's Law/Beer-Lambert's Law)

BEER-LAMBERT LAW

- States that concentration of an unknown analyte is **directly proportional to the light absorbed and inversely proportional to light transmitted.**
 - \checkmark Absorbance is proportional to the inverse log of transmittance

SINGLE-BEAM SPECTROPHOTOMETER



Photo reference: Henry's Clinical Diagnosis and Management by Laboratory Methods, 22nd edition

DOUBLE-BEAM SPECTROPHOTOMETER

- Double- beam in time 1 photodetector
- Double-beam in space 2 photodetectors (1- sample beam, 2- reference beam)

PARTS OF SPECTROPHOTOMETER

- 1. LIGHT SOURCE
 - ✓ Tungsten: for visible and near infrared region
 - ✓ Deuterium: for UV region

✓ Xenon discharge lamp: for UV and Visible region

- 2. ENTRANCE SLIT minimizes the entry of stray light to the monochromator
- 3. MONOCHROMATOR isolates specific wavelength
 - ✓ Prisms: light is **refracted**

- ✓ Diffraction gratings: light is **bent; most commonly used**
- ✓ Filters: light enters one side and is **reflected** on the other side.
- **4. EXIT SLIT** controls bandpass (total range to which wavelengths are transmitted. The narrower the bandpass, the grater the resolution)
- CUVETTE contains the solution (known as absorption cell/analytical cell/sample cell)
- 6. **PHOTODETECTOR** aids in the conversion of light transmitted to photoelectric energy
 - Barrier layer cell: simplest. Temperature sensitive. Radiation and visible region.
 - ✓ Photodiode: has excellent linearity.
 - Photomultiplier tube: most commonly used. Chemiluminiscence and Fluometry. Measures visible and UV region.
 - ✓ Phototube: cathode and anode enclosed in glass case. Fluometry.
- 7. **READ-OUT DEVICE** a monitor that displays the output

ATOMIC ABSORPTION SPECTROPHOTOMETRY

- Measures the amount of light that have been absorbed by a ground state atom
- For measurement of unexcitable metals like calcium and magnesium
- Hollow-cathode lamp: light source
- Atomizer: used for the conversion of ions to atoms
- Chopper: used to modulate amount of light from the hollow-cathode lamp

FLAME EMISSION PHOTOMETRY

- Flame permits the excitation of the electrons; after which, electrons return to a ground state thus radiation is emitted.
- Flame serves as both light source and cuvette.
- Internal standards used: Cesium and Lithium (preferred)
- For measurement of excited ions such as sodium (yellow) and potassium (violet).

• Calcium also shows a colored (brick red) flame

FLUOROMETRY

- Light is absorbed by atoms at a specific wavelength and is emitted at a longer wavelength (with lower energy)
- Light source: xenon lamp or mercury arc
- There are two monochromators
 - Primary monochromator: selects wavelength that is best absorbed by solution that is to be measured
 - ✓ Secondary monochromator: this prevents the incident light from striking the detector
- Disadvantage: Quenching

TURBIDIMETRY

- Measures light blocked by molecules
- Used for immunoglobulins, immune complexes and complement

NEPHELOMETRY

- Measures light scattered by molecules
- Used for measuring amount of antigen-antibody complexes

CHROMATOGRAPHY

- Separation is based upon differences in characteristics (both physical and chemical) of substances
- Used for amino acid determination, drugs and sugars

LIST DOWN ALL TYPES OF CHROMATOGRAPHY AND RESEARCH ON ITS PURPOSE/PRINCIPLE

POTENTIOMETRY

- Measures electric potential
- pH electrode glass electrode
- pCO₂ electrode
- ion selective electrode
 - ✓ Sodium: glass electrode
 - ✓ Potassium: Valinomycin gel
 - ✓ Chloride: Tri-N-octyl propyl ammonium chloride decanol

ELECTROPHORESIS

• Separation of proteins is aided by an electric current

| | IONS | POLE |
|----------|-----------|---------|
| POSITIVE | CATIONS + | CATHODE |
| NEGATIVE | ANIONS + | ANODE |

- pH of buffer: 8.6
- support materials:
 - ✓ Agarose gel separation by electric charges
 - ✓ Cellulose acetate separation by molecular size
 - ✓ Polyacrylamide gel separation by charge and molecular size

ELECTROPHORETIC PATTERN OF CERTAIN CONDITIONS

| Alpha ₁ -globulin flat curve | Juvenile cirrhosis |
|---|-------------------------------------|
| Alpha2-globulin band spike Nephrotic syndrome | |
| Beta-gamma bridging | Hepatic cirrhosis |
| Monoclonal gammopathy (gamma spike) | Multiple myeloma |
| Polyclonal gammopathy | Rheumatoid arthritis and malignancy |
| Small spike in Beta-region | Iron deficiency anemia |

CARBOHYDRATES

- Composed of carbon, hydrogen and oxygen
- Are water soluble
- Are important source of energy for the body's mechanisms
- Classifications:
 - ✓ Monosaccharides: Glucose, fructose and galactose
 - ✓ Disaccharides: maltose (glucose + glucose), lactose (galactose + glucose) and sucrose (fructose + glucose; most common non reducing sugar)
 - ✓ Polysaccharides: starch and glycogen

GLUCOSE

- Primary sugar found circulating in the body
- Carbohydrate metabolism:
 - ✓ Glycolysis: glucose → lactate or pyruvate → energy (\uparrow glucose)
 - ✓ Glycogenolysis: breakdown of glycogen to glucose (↑ glucose)
 - ✓ Glycogenesis: formation of glycogen from sugars for storage (↓glucose)
 - ✓ Gluconeogenesis: formation of glucose from non-carbohydrate sources (↓ glucose)
- Hormones for glucose regulation
 - ✓ Hypoglycemic
 - \circ $\;$ Insulin released by β cells of islet of Langerhans
 - Entry of glucose in the cell
 - Falsely low measurement of serum insulin is seen in the presence of **hemolysis.**
 - ✓ Hyperglycemic
 - $\circ~$ Glucagon released by α cells of islet of Langerhans
 - Primary hormone that increases glucose concentration.
 - NV in fasting plasma: 25-50pg/mL
 - Somatostatin released by delta cells of islet of Langerhans

PROPERTY OF MEDTECH REVIEW NOTES4 | P a g e

• Inhibits the action on inulin, GH and glucagon.

 \circ Cortisol

- o Epinephrine
- o Growth hormone
- o Thyroxine
- o ACTH
- MUST KNOW FOR SPECIMEN FOR GLUCOSE DETERMINATION
 - ✓ FBS should be obtained from an 8-10 hours fasting sample
 - ✓ In terms of glucose levels: capillary > venous but < arterial
 - ✓ Glucose is metabolized at:
 - Room temperature: 7 mg/dL/hr
 - 4°C: 2 mg/dL/hr
 - Tube of choice: Gray top (anticoagulant: _____; anti-glycolytic agent: _____)

GLUCOSE DETERMINATION

| METHOD | PRINCIPLE | REAGENTS | END PRODUCT/ COLOR REACTION |
|--|------------------|---|--------------------------------------|
| i. CHEMICAL | METHOD | | |
| A. OXIDATION REDU | CTION METHOD | | |
| 1. ALKALINE COPPER | | | |
| Folin-Wu - Modification: Benedict's Test | Copper Reduction | Alk. Copper reagent Phosphomolybdic Acid | Molybdenum – BLUE |
| Nelson- Somogyi | Copper Reduction | Alk. Copper reagent Arsenomolybdic | Molybdenum – BLUE |

| | | acid | | |
|--|---|--|---|--|
| Neocuproine 2. ALKALINE FERRIC REDU | Copper Reduction | Cuprous ions Neocuproine | Cuprous- Neocuproine Complex – YELLOW/ YELLOW ORANGE | |
| Autoanalyzer (Hagedorn-Jensen) | Ferricyanide reduction (Inverse Colorimetry) | K₃Fe(CN) ₆ | K ₃ Fe(CN) ₆ ⁻⁴ | |
| B. Condensation Method | | | | |
| Ortho-Toluidine | Dubowski reaction; Condensation Method | O-toluidine Glacial Acetic Acid | Glycosylamine – BLUE GREEN | |
| II. ENZYMATIC METHODS | II. ENZYMATIC METHODS | | | |
| Glucose Oxidase - Saifer Gernstenfield - Clarke electrode | Enzymatic - Colorimetric - Polarographic | Glucose Oxidase Peroxidase O-dianisidine | Oxidized o- dianisidine – ORANGE BROWN | |
| Hexokinase (REFERENCE METHOD) | Enzymatic | Hexokinase G6PD | NADPH ⁺ | |

LABORATORY TESTS

- Screening Tests
 - ✓ **Fasting Blood Sugar** 8-10 hours fasting

Normal: <100 mg/dL

• Impaired fasting glucose: 100-125 mg/dL

- **Diabetic:** ≥126 mg/dL
- ✓ 2-hours post-prandial a fasting blood samples is extracted, after which,
 - patient is given glucose load (75g). After 2 hours, blood glucose is measured.
 - Normal: <140 mg/dL
 - Impaired: 140-199 mg/dL
 - Diabetic: <u>></u> 200 mg/dL
- Confirmatory Tests
 - ✓ Oral Glucose Tolerance Test series of glucose testing
 - Patient is instructed to consume a normal to high CHO diet per day for 3 days prior to procedure
 - \circ Patient should be ambulatory
 - The patient should be finished within 5 minutes
 - Glucose loads: adult (75g), pregnant (100g) and children (1.75g/kg)
 - Normal: <140 mg/dL
 - Impaired: 140-199 mg/dL
 - Diabetic: <u>></u> 200 mg/dL
- Monitoring Test
 - ✓ HbA1c long term monitoring (2-3 months)
 - \circ $\;$ Dependent upon the patients' RBCs lifespan $\;$
 - \circ $\;$ Sample: EDTA whole blood, non-fasting $\;$
 - For every 1% increase in HbA1c = 35mg/dL change in plasma glucose!
- Fructosamine short term monitoring (2-3 weeks)
 - ✓ Levels of albumin affects results

CLINICAL SIGNIFICANCE

HYPERGLYCEMIA

Increased glucose levels

| | DIABETES MELLITUS | DIABETES INSIPIDUS | |
|-----------------------|---|----------------------------|--|
| | Involvement of insulin | Involvement of ADH | |
| | Polyuria | Polyuria (with no | |
| | | hyperglycemia) | |
| | High specific gravity urine | Low specific gravity urine | |
| | DIABETES | MELLITUS | |
| | TYPE 1 | TYPE 2 | |
| | Autoimmune process | Resistance to insulin | |
| | Insulin-dependent DM | Non-insulin dependent DM | |
| | Juvenile-onset DM | Adult-onset DM | |
| HYPOGLYCEMIA | Decreased glucose levels | | |
| | Whipple's triad: | | |
| | ✓ Low blood glucose level (<60 mg/dL) | | |
| | Presence of signs and symptoms | | |
| | ✓ Reversal of symptoms (if glucose is administered) | | |
| GESTATIONAL DM | Due to hormonal imbalance; occ | urs in pregnant women | |

| GLYCOGEN STORAGE DISEASES | | |
|---------------------------|---|--|
| ТҮРЕ | DEFECTS | |
| la – Von Gierke | Glucose-6-phosphatase | |
| II – Pompe | Lysosomal acid alpha glucosidase (GAA) acid maltase | |
| III – Cori-Forbes | Glycogen debranching enzyme | |
| IV – Andersen | Glycogen branching enzyme | |
| V – McArdle | Muscle phosphorylase | |
| VI – Hers | Glycogen phosphorylase | |
| VII – Tarui | Phosphofructokinase | |
| XI – Fanconi-Bickel | Glycogen transporter 2 | |
| 0 | Glycogen synthetase | |

LIPIDS AND LIPOPROTEINS

- Lipids are more commonly referred to as **fats**
- Insoluble in water but soluble in organic solvents
- Major forms of lipids:
 - ✓ FATTY ACIDS
 - Simplest
 - Building blocks of lipids
 - Saturated (no double bonds) or unsaturated (with double bonds)
 - ✓ TRIGLYCERIDES
 - Tri three molecules of fatty acids + one molecule of glycerol
 - Breakdown is facilitated by lipoprotein lipase 0
 - Primary cause of turbid serum 0
 - Main storage form of lipid 0
 - Requires a fasting specimen (12-14 hours) 0
 - > 500mg/dL highg risk for CAD
 - o RV: <500 mg/dL
- normal -
- 150-199 mg/dL borderline high
 - high TAG -
- 200-499 mg/dL >500 mg/Dl
- very high TAG (acute / recurrent

- pancreatitis)
- ✓ CHOLESTEROL
 - Not readily catabolized = not a source of fuel
 - No fasting is required
 - Four ringed structure made by hepatocytes
 - Constituent of cell membranes and precursor of some hormones (steroids: progestin, glucocorticoids, mineralocorticoids, androgen and estrogen).
 - Estrogen promotes transport and excretion of CHOLE
 - Should be measured in adults \geq 20 y/o at least once every 5 years.

- <200 mg/dL • RV:
 - desirable =
 - 200 239 mg/dL borderline high =
 - high cholesterol ≥240 =
- Two forms: esterified (60-70%) and free cholesterol (30-40%)
- o TAG and Chole most important lipids in management of CAD
- ✓ PHOSPHOLIPIDS
 - Structure: 2 fatty acids + phospholipid attached to glycerol
 - Most abundant lipid 0
 - Can also be found as surfactants in lungs. Def in neonates: RDS 0
 - Forms: Lecithin/phosphatidylcholine (major, 70-75%), sphingomyelin 0 (18-20%), phosphatidylserine and phosphatidylethanolamine (3-6%) and lysophosphatidylcholine (4-9%)
 - RV: 150 380 mg/dL (serum)
 - o Sphingomyelin
 - Component of cell membranes (RBC and nerve sheath)
 - Niemann-pick dxs: accumulation in the liver and spleen. (lipid storage disorder)
- ✓ LIPOPROTEINS
 - Carrier proteins for lipids
 - Major lipoproteins 0
 - A. Chylomicrons: largest and least dense.
 - Contains mostly TAG.
 - Produced in the intestines.
 - B. VLDL/Pre-beta lipoprotein. Made in the liver.
 - C. HDL/ Alpha Lipoprotein: smallest but most dense lipoprotein.
 - Removes excess cholesterol from cells.
 - Produced by liver and intestine.
 - Maintains balance of cholesterol.

- CDC Reference method for determination: ultracentrifugation, precipitation with heparin-MnCl₂ and Abell-Kendal assay.
- **D. LDL/Beta Lipoprotein:** Marker of CHD risk.
 - most cholesterol-rich and most atherogenic.
 - major end-product of VLDL catabolism.

| | HDL | LDL | VLDL | Chylomicrons | |
|------------------|-------------------|-----------------|------------------|----------------|--|
| | Good | Bad cholesterol | Carrier of | Carrier of | |
| | cholesterol | | endogenous | exogenous TAG | |
| | | | TAG | | |
| Migration | Alpha | Beta | Pre-beta | Origin | |
| Size | 70-100 | 100-300 | 2000 | > 2000 | |
| Density | 1.063-1.125 | 1.019-1.063 | 0.95-1.006 | < 0.95 (top | |
| | (bottom layer) | | | layer) | |
| Protein | 50% | 20% | 4-8% | 1-2% | |
| | LIPID CONTENT (%) | | | | |
| Free cholesterol | 3-5 | 6-8 | 4-8 | 1-3 | |
| Esterified | 15-20 | 45-50 | 16-22 | 2-4 | |
| TAG | 2-7 | 4-8 | 45-65 | 80-95 | |
| Phospholipid | 26-32 | 18-24 | 15-20 | 3-6 | |
| Lipid: protein | 50:50 | 80:20 | 90:10 | 99:1 | |
| ratio | | | | | |
| Apolipoproteins | A-1, A-II, C | B-100, E | B-100, A-1, C, E | A1, B-48, C, E | |

- Minor lipoproteins:
 - A. IDL Subclass
 - Migrates either in the pre-beta or beta region
 - Major apolipoprotein: Apo B-100
 - B. Lp(a) aka sinking pre-beta, linked to atherosclerosis
- \circ Abnormal lipoproteins: LpX linked to obstructive jaundice, β-VLDL aka floating β lipoprotein

- Indicator of cholestasis.
- Beta-VLDL: floating beta lipoprotein
 - Migrates with LDL in beta region found in type 3 hyperlipoproteinemia or dysbetalipoproteinemia.
 - VLDL rich in cholesterol

APOLIPOPROTEINS

- Apo A major protein component of HDL
 - ✓ Apo A-I: LCAT activator
 - ✓ Apo A-II: may inhibit hepatic & lipoprotein lipases; increases plasma TAG
- Apo B major protein component of LDL
 - ✓ Apo B-48: found in chylomicron
 - ✓ Apo B-100: synthesized in liver; found in VLDL & LDL
- Apo C major protein component of VLDL; minor in HDL and LDL
 - Apo C-I: may inhibit the hepatic uptake of VLDL and cholesterol ester transfer protein
 - ✓ Apo C-II: if deficient there would be reduced clearance of TAG-rich lipoproteins
 - ✓ Apo C-III: main form found in HDL. Lipolysis of TAG-rich lipoproteins is inhibited by this form
- Minor apolipoproteins
 - ✓ Apo D: aids in the activation of LCAT
 - ✓ Apo E: Arginine rich
 - o Apo E-I
 - o Apo E-II: associated with type III hyperlipoproteinemia
 - Apo E-III: most common isoform
 - Apo E-IV: associated with high levels of LDL, increased risk for Alzheimer's and CHD

✓ Apo F, Apo H and Apo J

LIPID QUANTITATION

- 1. TRIGLYCERIDES
 - **A.** CHEMICAL METHOD (Van Handel and Zilversmit method and Modified Van Handel Zilversmit method)

STEP 1: EXTRACTION BY ORGANIC SOLVENT

- $\checkmark\,$ This is for the removal of lipids from proteins
- ✓ There is an additional adsorption step to remove non-triglycerides

STEP 2: SAPONIFICATION OR HYDROLYSIS BY KOH IN ETOH

✓ TAG → fatty acids + glycerol

STEP 3: OXIDATION

✓ Oxidizes glycerol to measurable compounds

STEP 4: COLORIMETRY

- ✓ 500-600nm
- **B.** ENZYMATIC METHOD lipase and glycerokinase serve in the initial enzymatic reaction

2. TOTAL CHOLESTEROL

- A. COLOR REACTION
 - Liebermann Burchardt Reaction
 - Principle: Dehydration and Oxidation of cholesterol to form a colored compound
 - ✓ Reagents: Acetic anhydride-sulfuric acid
 - ✓ End product: Cholestadienyl monosulfonic acid GREEN
 - Salkowski Reaction
 - ✓ Methods:
 - Bloor's method extraction of cholesterol by Bloor's, L-B reaction

- Abell-Kendall method extraction of cholesterol by Zeolite, L-B reaction
- B. Enzymatic Method
 - Cholesterol oxidase reaction measures amount of hydrogen peroxide produced.
 - Interference: (+) hemoglobin, (-) Bilirubin and ascorbic acid.

CDC reference method: Abell, Levy and Brodie method (3 step method: Saponification, extraction, and colorimetry)

3. HDL

Methods: Electrophoresis & Modified Bloor's

- 4. Ultracentrifugation: density gradient
 - a. Reference method for quantitation of lipoprotein.
 - b. Svedverg (s) units
 - c. Reagent: potassioum bromide solution with 1.063 density.
- 5. Electrophoresis
- 6. Chemical precipitation (HDL and LDL)

Put here your own mnemonic for the classification

Formula for LDL-Cholesterol (LDL-C) = total cholesterol – HDL- VLDL

WRITE THE FRIEDEWALD AND DELONG'S FORMULA

| Triglycerides | <150 mg/dL | 150-199 mg/dL | 200-499 mg/dL |
|--------------------------|------------|---------------|-----------------------|
| HDL-C | 40 mg/dL | n/a | n/a |
| LDL-C | <130 mg/dL | 130-159 mg/dL | 160-189 mg/dL |
| Total Cholesterol | <200 mg/dL | 200-239 mg/dL | <u>></u> 240 mg/dL |

| STRATIFIED RISK FACTORS FOR CHD | | | |
|---------------------------------|-----------------------|-------------------|--|
| Age (in years) | Moderate Risk (mg/dL) | High Risk (mg/dL) | |
| 2-19 | >170 | >185 | |
| 20-29 | >200 | >220 | |
| 30-39 | >220 | >240 | |
| 40- above | >240 | >260 | |

| FREDERICKSON AND LEVY'S CLASSIFICATION OF HYPERLIPOPROTEINEMIA | | | |
|---|--|--|--|
| TYPES | STANDING PLASMA TEST* | GEL ELECTROPHORESIS | |
| ΤΥΡΕ Ι | Creamy layer – Clear plasma | Normal | |
| TYPE IIa | Negative – Clear plasma | Increased β band | |
| TYPE IIb | Negative – Cloudy plasma | Increased β and pre- β band | |
| TYPE III | Occasional – Cloudy plasma | Increased pre- β band | |
| | | (broad β band) | |
| TYPE IV | Negative – Cloudy plasma | Increased α2 band | |
| TYPE V | Creamy layer – Cloudy plasma | Increased α2 band | |
| TYPE I TYPE IIa TYPE IIb TYPE III TYPE IV TYPE V | Creamy layer – Clear plasma Negative – Clear plasma Negative – Cloudy plasma Occasional – Cloudy plasma Negative – Cloudy plasma Creamy layer – Cloudy plasma | Normal Increased β band Increased β and pre- β band Increased pre- β band (broad β band) Increased α2 band Increased α2 band | |

*plasma is placed in a test tube and stored at 4°C overnight. Presence of "cream" floating and turbidity of plasma is observed for presence of chylomicron and VLDL respectively

| LIPID STORAGE DISEASES | | |
|------------------------------|--|--|
| Fabry's disease | alpha galactosidase deficiency | |
| Gaucher | beta galactosidase deficiency | |
| Krabbe | cereboside beta galactosidase deficiency | |
| Metachromatic Leukodystrophy | arylsufatase A deficiency | |
| Niemann Pick | sphingomyelinase deficiency | |
| Sandhoff | hexosaminidase A and B deficiency | |
| Tay Sach | hexosaminidase A deficiency | |

| LIPID | PROFILE | |
|-----------|-----------------|------|
| Desirable | Borderline High | High |
| | | |

PROTEINS

- Composed of carbon, hydrogen, oxygen and nitrogen
- Most abundant macromolecule in the body
- Amphoteric in nature
- Synthesized in the liver except for immunoglobulins (which are synthesized by plasma cells)
- In alkaline Ph = proteins are negatively charged
- In acidic pH = proteins are positively charged
- Structures:
 - ✓ Primary: amino acid sequence
 - ✓ Secondary: conformations could either be alpha-helix, beta-pleated, sheath and bend form
 - ✓ Tertiary: actual 3D configuration
 - ✓ Quaternary: protein already consists of 2 or more polypeptide chains

PLASMA PROTEINS

| FRACTIONS | SPECIFIC PROTEINS |
|------------|--|
| Prealbumin | Aka transthyretin |
| | Marker for malnutrition |
| | 2nd most predominant protein in the CSF |
| | Transfer T4 and retinol (Vitamin A) |
| | ↑ Alcoholism, Chronic renal failure, steroid txm. ↓ poor |
| | nutrition |
| | RV: 18 – 45 mg/ dL |
| Albumin | Most abundant protein |
| | Acts as a transport protein |
| | Negative acute phase reactant |
| | Maintains osmotic pressure |
| | Elevated in Cystic fibrosis |

| | Negative acute phase reactant |
|-----------------|--|
| | Low level: nephrotic syndrome |
| | Analbuminemia: albumin absence |
| | Bisalbuminemia: there are 2 bands seen in the albumin |
| | region |
| | Hypoalbuminemia: low levels of albumin |
| | RV: 3.5 – 5.0 g/dL |
| GLOBULIN | Measurement: TP – A = G |
| | ↑ Early cirrhosis |
| | RV: 2.3 – 3.5 g/dL |
| Alpha₁ globulin | Alpha ₁ antitrypsin (AAT) |
| | Acute phase reactant. Released from WBC to combat inf |
| | Protease inhibitor |
| | NV 2.3-3.5 mg/dL |
| | AFP |
| | Tumor marker for hepatocellular carcinoma (hepatic and |
| | gonodal cancer). |
| | Increased in presence of twins and neural tube defect. |
| | Decreased in down syndrome. |
| | Screening for maternal AFP for NTD and DS: 15 and 20 |
| | weeks of gestational age. |
| | RV: 5 ng/ml both in adults and children |
| | Alpha-1-acid-glycoprotein (orosomucoid) |
| | Carrier proteins for steroid hormones (Progesterone). |
| | Increased in neonatal bacterial inf. |
| | RV: 55-140 mg/dL |
| | Alpha ₁ -antichymotrypsin |
| | Inhibits serine Proteinases |
| | Acute phase reactant. Binds and inactivates PSA |
| | Associated with Alzheimer's dxs, \downarrow in liver dxs |
| | RV: 30 – 60 mg/dL |
| | Gc-globulin |

| | Affinity with vit D and actin. | |
|-----------------------------|--|-----|
| | Alpha-1-lipoprotein | |
| | Transports lipids | |
| Alpha ₂ globulin | Ceruloplasmin | |
| | Transports copper | |
| | ↓ Wilson's Disease (kayser-fleisher rings: deposition in | |
| | cornea) Menkes' kinky-hair syndrome | |
| | Method: copper oxidase activity. | |
| | RV: 18-45 mg/dL | |
| | Haptoglobin | |
| | transports free hemoglobin | |
| | Acute phase reactant | |
| | Alpha ₂ macroglobulin | |
| | Inhibits protease | |
| | 10x elevation is seen in nephrosis | Gam |
| | RV: 150-420 mg/dL | |
| Beta globulin | Pre-beta-lipoprotein | |
| | Transports lipids (VLDL, TAG) | |
| | Beta-lipoprotein | |
| | Transports lipids (LDL, CHOLE) | |
| | Beta ₂ microglobulin | |
| | Light chain component of HLA | |
| | Elevated in RA and SLE, MM, HIV and Renal Failure. | отц |
| | RV: 0.2-2.8 ug/dL | |
| | Complement System | • |
| | Immune response | |
| | \uparrow in inflammation \downarrow DIC, hemolytic anemia and malnutrition | |
| | CRP | |
| | Acute phase reactants | |
| | Promotes phagocytosis | |
| | Cardiac marker | |
| | RV: <1.0 mg/dL | |

| | Fibrinogen |
|--------------|--|
| | Protein present in plasma but not in serum |
| | Largest protein in the blood |
| | Precursor of fibrin clot |
| | Method for measurement: Parfentjev method |
| | RV: <1.0 |
| | Hemopexin |
| | Acute phase reactant |
| | Binds heme |
| | Indicates early hemolysis |
| | RV: 50-115 mg/dL |
| | Transferrin/SIderophilin |
| | Transports iron |
| | \uparrow hemochromatosis, \downarrow liver dxs, malnutrition, nephrotic syn. |
| nma globulin | Immunoglobulins: synthesized in plasma cells |
| C C | IgG most abundant |
| | IgA found in mucous secretions |
| | IgM first to appear |
| | IgE allergy and anaphylactic reactions |
| | IgD present in surface of B cells |
| | CRP (in other references) |

OTHERS PROTEINS

- Myoglobin
 - ✓ Carries oxygen in muscles
 - ✓ Nephrotoxin
 - ✓ Marker of chest pain (angina) and early det. Of AMI
 - \checkmark 12-3 hours of onset, peak at 8-10 hours
 - ✓ ↑ AMI, angina, rhabdomyolysis, muscle trauma, acute renal failure
- Troponin (cTnl)

- ✓ Regulates actin and myosin
- ✓ Marker for acute coronary syndrome
- ✓ Most important marker for AMI
- ✓ RV: <0.1 ng/mL</p>
- BNP
 - ✓ ↑ ventricular systolic and diastolic dysfunction
 - ✓ Congestive heart failure
- Cystatin C
 - ✓ Marker for kidney function (GFR)
 - ✓ Endogenous renal marker
- Beta-trace protein
 - ✓ Marker for CSF leakage
- Amyloid
 - ✓ Fibrous protein aggregates
- Bence-Jones protein: protein found in patients with Multiple Myeloma
 - ✓ Unique feature: Coagulates at 40-60°C and dissolves at 100°C
 - ✓ Method for measurement: Immunofixation
 - ✓ Electrophoretic pattern: "tall spike" or "monoclonal peak"

METHODS FOR ALBUMIN QUANTITATION

- Electrophoresis
- Biuret Method
 - ✓ Principle: measurement of at least 2 peptide bonds and formation of a violet colored chelate.
 - ✓ Measured at 540nm
 - ✓ Reagents: Rochelle salt (NaK tartrate), Alkaline CuSO₄, NaOH and KI
- Kjeldahl Method
 - ✓ Reference method

- ✓ Based upon the digestion of protein and measurement of nitrogen content of proteins
- ✓ Albumin nitrogen x 6.25 = albumin
- Lowry (Folin-Ciocalteu) method
 - ✓ Reagent: Phosphotungstomolybdic acid
- Dye-binding method
 - ✓ BCG: most commonly used
 - $\checkmark~$ BCP: most sensitive, specific and precise
 - \checkmark H-ABA: with salicylates and bilirubin interferences

CSF OLIGOCLONAL BANDING

- Multiple sclerosis: 2 or more IgG bands in the gamma region
- Other dxs with two more bands in the CSF: Encephalitis, neurosyphilis, Gullain-Barre syndrome, neoplastic dxs
- Serum banding in CSF: Leukemia, lymphoma and viral inf.

AMINOACIDOPATHIES

- Alkaptonuria
 - ✓ Absence of homogentisate oxidase in tyrosine pathway
 - ✓ Ochronosis: tissue pigmentation
 - ✓ Darkening of urine upon standing
- Homocystinuria
 - ✓ Impaired activity of cystathionine B-synthetase
 - \checkmark Elevated homocysteine and methionine in blood and urine
 - ✓ Screening test: Modified Guthrie Test (L-methionine sulfoximine)
- MSUD
 - ✓ Reduced or absence of a-ketoacid decarboxylase
 - \checkmark Accumulation of leucine, isoleucine and valine.
 - ✓ Screening test: Modified Guthrie Test (4-azaleucine)

- Phenylketonuria
 - ✓ Def of phenylalanie hydrolase
 - ✓ Phenylpyruvic acid in both blood and urine
 - ✓ Musty odor urine
 - ✓ Screening: Guthrie Bacterial Inhibition Assay (Bacillus subtillis)
- Tyrosinemia
 - ✓ Def. of either of these enzymes tyrosine aminotransferase, 4hydroxyphenylpyruvic acid oxidase, fumarylacetoacetate
 - ✓ Increased levels of **methionine** and **p-hydroxyphenolpyruvic acid** in blood.
 - ✓ Results to liver damage or cirrhosis

NON – PROTEIN NITROGEN

- Monitor and asses renal function.
- Result from the breakdown of protein and nucleic acids.

UREA

- Most abundant (45-50%) NPN
- Major end product of protein metabolism
- First metabolite to increase in kidney dxs
- BUN:Crea Ratio 10:1-20:1
- Urea is decreased in severe hepatic dxs
- Methods:
 - ✓ Micro-Kjeldahl Nesslerization method
 - Indirect method
 - Nitrogen x 2.14 = urea x 0.467 = BUN
 - ✓ Rosenthal method
 - Direct method
 - Diacetyl monoxime method
 - ✓ Enzymatic method
 - Urease
 - ✓ IDMS
 - o Reference method

CREATININE

- Major end product of muscle catabolism
- Produced by three AA: methionine, arginine and lysine
- Index of overall renal function
- Evauluate fetal kidney maturity
- 100% is excreted

- Creatine: 100% is reabsorbed by kidney
- RV: Male = 0.9 1.3 mg/dL (80 115 umol/L) Female = 0.6 - 1.1 mg/dL (53 - 97 umol/L)
- Methods:
 - ✓ Jaffe reaction
 - ✓ Note: falsely elevated in px taking caphalosporin
 - **Color reagent:** Alkaline picrate
 - Lloyd's reagent: sodium aluminum silicate
 - o Fuller's Earth: aluminum magnesium silicate
 - Enzymatic method
 - Creatinine aminohydrolase CK Method
 - o Creatinase-hydrogen peroxide method

AMINO ACIDS

• Building blocks of proteins

AMMONIUM

- Used to monitor hepatic coma
- Important indicator of Reye's syndrome

URIC ACID

- Major product of purine metabolism
- Forms crystals in joints (tophi)
- Methods:
 - ✓ Folin method
 - ✓ Henry's method
 - ✓ Enzymatic method

LIVER FUNCTION TEST



Figure 21-2 Schematic summary of the pathway of bilirubin (*Bili, in brown circles*) transport and metabolism. Bilirubin is produced from metabolism of heme, pri in the spleen, and is transported to the liver bound to albumin. It enters the hepatocyte by binding to a transporter protein (*red crescents*) and crosses the cell mem (*circled 1*), thus entering the cell. It binds to Y and Z proteins (*not shown*) and then to ligandin for transport to the smooth endoplasmic reticulum (SER). In the SER, bi is conjugated to glucuronic acid by UDP-glucuronyl transferase 1 (*circled 2 and labeled GT*), producing monoglucuronides and diglucuronides of bilirubin—Bili-Gu ar (Gu). Conjugated bilirubin is then secreted into the canaliculi (*circled 3*) by the adenosine triphosphate-binding cassette transporter protein MRP2/cMOAT/ABCC2 (*as blue crescents*). In overproduction disease (A), such as hemolytic anemia, unconjugated bilirubin is produced at rates that exceed the ability of the liver to clear it, le to a usually transient increase in unconjugated bilirubin in serum. In both Gilbert's and Crigler-Najjar syndromes, mutations in the gene encoding UDP glucuronyl trans (*UDPGT1A1*), shown at **C** in the figure, result in buildup of unconjugated bilirubin in hepatocytes and ultimately in serum. In Gilbert's syndrome, there may also be a in the bilirubin transporter protein, shown at **B** in the figure. Mutations in the *MRP2/cMOAT/ABCC2* gene result in defective secretory proteins, causing buildup of conju bilirubin in hepatocytes and, ultimately, in serum, resulting in the Dubin-Johnson syndrome (**D**), an autosomal recessive disease. Conjugated hyperbilirubinemia found in the Rotor syndrome, possibly virus induced. In adults, blockade of any of the major bile ducts, especially the common bile duct, by stones or space-occu lesions such as tumors (**E**), is the most common cause of conjugated hyperbilirubinemia. *Hb*, Hemoglobin; *RE*, red blood cell.

Photo reference: Henry's Clinical Diagnosis and Management by Laboratory Methods, 22nd edition

METHODS

- Van den Bergh: color reaction for bilirubin
 - ✓ Color reagent: Diazo reagent
 - Product: Azobilirubin
 - ✓ Evelyn-Malloy
 - Medium: ACID
 - Dissociating agent: 50% methanol
 - End color: red/reddish purple
 - ✓ Jendrassik-Grof
 - Medium: ALKALINE
 - **o** Dissociating agent: Caffeine sodium benzoate
 - End color: blue
- Icterus index
 - ✓ Applicable to newborn and neonates
- Bromsulfonpthalein Dye Excretion test
 - ✓ Rosenthal White
 - o Double collection method
 - o Collection is done after 5 mins and 30 mins
 - Reference values: 50% dye retention (5mins) 0% (30mins)
 - ✓ Mac Donald
 - \circ Single collection method
 - Collection: done after 45 mins (<u>+</u> 5% dye retention)

DISEASES

- Gilbert syndrome: defect in transport protein in liver
- Crigler-Najjar syndrome: defective conjugation due to deficiency of UDP-GTase
- Dubin-Johnson syndrome: defective excretion due to blockage by stones

ENZYMES

• Catalyzes reaction

DEFINITION OF TERMS

- Apoenzyme: protein portion of enzyme without cofactor
- Holoenzyme: complete active enzyme
- Active site: site where enzymatic reaction occurs
- Allosteric site: site other than the active site
- Isoenzyme: forms of enzyme that are different from each other but still catalyzes same reaction

CATEGORIES

1. Oxidoreductase

- ✓ For oxidation/reduction reactions
- ✓ Ex: LDH, G6PD and Malate dehydrogenase

2. Transferase

- ✓ Catalyzes transfer of groups from one substrate unto another
- ✓ Ex: AST, ALT, CK, GGT

3. Hydrolase

- ✓ Hydrolysis
- ✓ Ex: ACP, ALP, 5'NT, AMS, LPS, CHS

4. Lyase

- ✓ Removal of groups but with no hydrolysis
- ✓ Ex: Aldolase

5. Isomerase

✓ Interconversion of isomers

6. Ligase

- ✓ Joins to 2 substrate molecules
- ✓ Ex: synthases

| ENZYME | METHODS | SUBSTRATES | FACTS |
|---|--|--|--|
| | HEPATIC | ENZYME PROFILE | |
| ALP Liver Kidney Bone Placenta Intestine WBC | Bodansky Shenowara Jones King-Armstrong Bessy Lowry-Brock | B-glyceroPO ₄ B-glyceroPO ₄ p-nitrophenylPO ₄ p-nitrophenylPO ₄ | Optimum pH: 10 Greatly elevated in Paget's disease Avoid using EDTA-Citrate- Oxalate |
| ALT (SGPT) Liver RBCs | Reitman-Frankel (DNPH) | Alanine α-keto | Liver-specific Marked elevation with viral hepatitis De ritis ratio: >1 = viral; <1 = non-viral |
| LD All tissues | Wacker Method (forward) Wrobleuski La Due (reverse) Wrobleuski Cabaud Berger Broida | | NAD+ (cofactor) LD4 and LD5 Storage: 25°C up to 24 hours |
| GGT Canaliculi of hepatic cells, Kidney, Prostate and Pancreas | SZAZ | Gammaglutamyl p- nitroanilide | Most sensitive marker for alcoholic hepatitis |
| ChE | Pseudo- Michael; Ellman | Acetylcholine | ChE: CNS, RBC, Lungs, Spleen Pseudo: Liver – Succinylcholine (relaxant); |

PROPERTY OF MEDTECH REVIEW NOTES17 | P a g e

| | | | anesthetic poisoning |
|--|--|------------------|---|
| | CARDIAC | ENZYME PROFILE | |
| CK Cardiac, skeletal and brain tissues | Tanzer-Gilvarg (forward) Oliver-Rosalki (reverse) | | CK-BB (fastest migrating; most anodal), CK-MB, CK- MM (slowest; least anodal) Sensitive indicator of AMI & Duchenne disorder Highest elevation of total CK: Duchenne's muscular dystrophy |
| AST (SGOT) Liver, heart, skeletal muscle | Karmen Method (Ph 7.5; 340 nm) | Aspartate α-keto | Light and pH sensitive Most sensitive enzyme for skeletal muscle disease Inhibited by all anticoagulants except heparin (but ammonium heparin should not be used) |
| LD All tissues | Wacker Method (forward) – pH 8.8 Wrobleuski La Due (reverse) – pH 7.2 Wrobleuski Cabaud Berger Broida | | LD1 (anodic & heat stable) LD2 (heat stable & major isoenzyme in the sera of healthy persons) LD5 (cathodic & cold labile) Flipped ratio: LD1>LD2 |

| Myoglobin | | | LD/HBD(LD1) ratio: 1.2- 1.6; if 0.8-1.2 suspect for MI Responsible for O ₂ supply of striated muscle |
|-----------------------------------|--|--|---|
| | | | (tropomyosin-binding) & C (calcium-binding) |
| | ACUTE PAN | ICREATITIS PROFILE | |
| AMS Salivary glands, | Saccharogenic Iodometric/Amyloclastic Chromogenic | Pancreatic AMS: diastase Salivary AMS: | MicroAMS: unbound (free) |
| Pancreas | Kinetic Method | ptyalin | MacroAMS: bound to IgG and IgA |
| | | | Earliest pancreatic marker Smallest enzyme in size Salivary AMS: inhibited by wheat germ lectin |
| LPS Pancreas | Cherry-Crandall Sigma-Tietz | Olive Oil/Triolein (pure form of TAG) | End product: Fatty Acids |
| | litration | | Most specific pancreatic marker |
| | PROSTATI | C CANCER PROFILE | |
| ACP RBC Prostate | Chemical Inhibition Test RBC-ACP: inactivated by Cu++, unaffected by Tartrate P-ACP: unaffected by Cu++, inactivated by | Organophosphates | Very labile (add 5M acetate buffer/citrate tablet to preserve) |

PROPERTY OF MEDTECH REVIEW NOTES18 | P a g e

| | Tartrate | | |
|----------|--------------------|---------------------|---|
| PSA | | | Most useful for tumor marker for prostate cancer |
| | | | RR: 0-4ng/mL |
| | | | |
| ACUTE | MYOCARDIAL INFARCT | ON MARKERS (Bishop, | Rodriguez, Coderes) |
| ACUTE | MYOCARDIAL INFARCT | ON MARKERS (Bishop, | Rodriguez, Coderes) |
| Marker | Onset (hours | Peak (hours) | Duration (hours) |
| ACUTE | MYOCARDIAL INFARCT | ON MARKERS (Bishop, | Rodriguez, Coderes) |
| Marker | Onset (hours | Peak (hours) | Duration (hours) |
| Myoglobi | in 1-3 | 5-12 | 18-30 |
| ACUTE | MYOCARDIAL INFARCT | ON MARKERS (Bishop, | Rodriguez, Coderes)Duration (hours)18-307days up to 10-14days |
| Marker | Onset (hours | Peak (hours) | |
| Myoglobi | in 1-3 | 5-12 | |
| Trop I | 3-4 | 10-24 | |
| ACUTE | MYOCARDIAL INFARCT | ON MARKERS (Bishop, | Rodriguez, Coderes)Duration (hours)18-307days up to 10-14days5-10 days |
| Marker | Onset (hours | Peak (hours) | |
| Myoglobi | in 1-3 | 5-12 | |
| Trop I | 3-4 | 10-24 | |
| Trop T | 3-6 | 12-18 | |
| ACUTE | MYOCARDIAL INFARCT | ON MARKERS (Bishop, | Rodriguez, Coderes)Duration (hours)18-307days up to 10-14days5-10 days48-72 |
| Marker | Onset (hours | Peak (hours) | |
| Myoglobi | in 1-3 | 5-12 | |
| Trop I | 3-4 | 10-24 | |
| Trop T | 3-6 | 12-18 | |
| CK-MB | 4-6 | 12-24 | |
| ACUTE | MYOCARDIAL INFARCT | ON MARKERS (Bishop, | Rodriguez, Coderes)Duration (hours)18-307days up to 10-14days5-10 days48-725 days |
| Marker | Onset (hours | Peak (hours) | |
| Myoglobi | in 1-3 | 5-12 | |
| Trop I | 3-4 | 10-24 | |
| Trop T | 3-6 | 12-18 | |
| CK-MB | 4-6 | 12-24 | |
| AST | 6-8 | 24 | |

ELECTROLYTES

ELECTRONEUTRALITY

Na⁺ + K⁺ + 7 = Cl⁻ + HCO₃⁻ + 25

ANION GAP: difference between unmeasured anions and unmeasured cations

AG = Na⁺ - (Cl⁻ + HCO₃⁻)

 $AG = Na^+ + K^+ - (Cl^- + HCO_3^-)$

Ref. range: 7-16 mmol/L

Ref. range: 10-20 mmol/L

| ELECTROLYTES | INFORMATION | | |
|--------------|---|------------------------------------|--|
| Sodium | Most abundant cation in the ECF | | |
| | Has the greatest influence in serum osmolality | | |
| | Aldosterone: responsible for the reabsorption in tubules | | |
| | Atrial natriuretic factor: blocks secretion of both aldosterone & renin | | |
| | Hyponatremia is the most comm | on electrolyte disorder | |
| | ~for every 100mg/dL increase in t | blood glucose, there is a decrease | |
| | by 1.6 mmol/L of serum sodium | - | |
| | Hypernatremia | Hyponatremia | |
| | Excessive water loss | Increase water retention | |
| | Water intake is decreased | Water imbalance | |
| | Increase Na+ intake/retention | Sodium loss | |
| | Methods: | | |
| | Flame Emission Photometry (FEP) - yellow | | |
| | ISE – glass aluminum silicate | | |
| | AAS | | |
| | Colorimetry - Albanese Lein | | |
| Potassium | Major intracellular cation | | |
| | Regulates ICF volume regulation and H+ concentration, | | |
| | contraction of the heart and excitability of mucles | | |
| | Hyperkalemia | Hypokalemia | |

| | Extracellular shift | Renal loss |
|----------|--|--------------------------------------|
| | Increased intake | GLIOSS |
| | Renal excretion is decreaed | Intracellular shift |
| | Artifactual (eg. Hemolysis | Intake is decreased |
| | thrombocytosis) | |
| | Methods: | |
| | FEP – violet | |
| | ISE – valinomycin gel | |
| | AAS | |
| | Colorimetry – Lockhead and Purc | ell |
| Chloride | Major extracellular anion | |
| | Only anion that serves as an enzy | me activator |
| | Sweat chloride: diagnosis for cyst | ic fibrosis |
| | Hyperchloremia | Hypochloremia |
| | GI loss | Hyperparathyroidism |
| | Diabetic ketoacidosis | Low reabsorption of HCO ₃ |
| | Low Na+ levels | |
| | Mineralocorticoid excess & | |
| | deficiency | |
| | Methods: | |
| | Mercurimetric method: Schales a | nd Schales (indicator: |
| | diphenylcarbazone) | |
| | Coulometric amperometric titrati | on: Cotlove chloridometer |
| | Colorimetry | |
| | ISE – electrodes with AgCl membr | anes |
| Calcium | Ion that is the most abundant in t | he body |
| | 3 rd most abundant in blood | |
| | 99% (bone) and 1% (blood) | |
| | PTH: promotes bone resorption | |
| | Calcitonin: promotes bone depos | ition |
| | Vitamin D3: promotes intestinal a | bsorption of calcium |
| | Methods: | |

PROPERTY OF MEDTECH REVIEW NOTES20 | P a g e

| | Clark & Collip Precipitation (titration with KMnO ₄) |
|--------------|--|
| | FEF |
| | AAS – Telefence method |
| • • | ISE – liquia memorane |
| Magnesium | 2 th major cation in ICF |
| | 4 th most abundant ion in the body |
| | 2 nd mostly affected by hemolysis (after potassium) |
| | Methods: |
| | AAS – reference method |
| | Colorimetry – Calmagite (reddish-violet) |
| | Dye method – Titan yellow |
| Bicarbonate | 2 nd most abundant ECF anion |
| | Acts as buffer |
| | Diffuses out of the cell in exchange for chloride |
| | Increased levels: alkalosis, vomiting, hypokalemia |
| | Decreased levels: acidosis |
| | Methods: |
| | ISE – Clark electrode |
| | Enzymatic method: Phosphoenolpyruvate carboxylase & |
| | dehydrogenase |
| Phosphorus | |
| riiospiiorus | Inversely propertional to calcium and DTH |
| | |
| | Best preserved by acidic filtrate |

SUMMARY (memorize this 🙂)

| ELECTROLYTES | FUNCTION |
|--------------------------|--|
| HCO ₃ , K, Cl | Acid-Base Balance |
| Ca, Mg | Blood coagulation |
| Mg, Ca, Zn | Cofactors in enzyme activation |
| K, Mg, Ca | Myocardial rhythm and contractility |
| K, Ca, Mg | Neuromuscular excitability |
| Mg, PO ₄ | Production and use of ATP from glucose |
| Mg | Regulation of ATPase pumps |
| Na, K, Cl | Volume and osmotic regulation |

BLOOD GAS

DEFINITION OF TERMS:

- Acid: a compound that could donate a H+ ion
- **Base**: a compound that could **accept** a H+ ion
- Acid-Base Balance: a mechanism by which the pH of blood is maintained at 7.35-7.45 for homeostasis
- Buffer: a weak acid/base with its conjugate salt that resists changes in Ph

ACID BASE BALANCE

HENDERSON-HASSELBACH EQUATION

• Implicates the relationship between pH, and the two involved organs - lungs and kidneys

$$pH = 6.1 + \log \frac{HCO_3}{PCO2 \ x \ 0.0307}$$

EXPANDED FORM:
$$pH = 6.1 + \log \frac{[TCO2 - (PCO2 x 0.03)]}{PCO2 x 0.03}$$

| FOUR BASIC ABNORMAL STATES | | | | | | |
|----------------------------|----|------------------|--------------------------------|------|---|-------------------------|
| Imbalance | рН | pCO ₂ | H ₂ CO ₃ | HCO₃ | Primary compensation | Seen in: |
| Respiratory Acidosis | 4 | 1 | 1 | N | Kidneys retain bicarbonate & excrete hydrogen | Pneumonia, emphysema |
| Respiratory | 1 | \checkmark | 1 | N | Reverse of respiratory | Hyperventilation, |

| Alkalosis | | | | | acidosis | early salicylate poisoning |
|------------------------|---|---|---|---|--|---|
| Metabolic Acidosis | • | Ν | N | ¥ | Hyperventilate (CO ₂ blew off) | Diabetic ketoacidosis, renal disease and prolonged diarrhea |
| Metabolic Alkalosis | 1 | Ν | N | 1 | Hypoventilation (CO ₂ retention) | Vomiting, antacids, NaHCO₃ infusion |

EVALUATING ACID-BASE DISORDERS

- 1. Determine if the pH is high (alkalosis) or low (acidosis)
- **2.** Compare pCO_2 and HCO_3 to normal values
 - ✓ If pCO₂ is opposite to pH = respiratory
 - ✓ If HCO₃ is in the same direction with pH = metabolic
- 3. If pH is within normal range, full compensation has occurred
- **4.** if main compensatory mechanism has already occurred yet the pH is still out of range, **partial compensation** happened.

NORMAL VALUES

- pH: **7.35 7.45**
- pCO₂: **35-45 mmHg**
- pO₂: **81-100 mmHg**
- HCO3: 21-28 mEq/L
- TCO₂: arterial (19-24 mmol/L); venous (22-26 mmol/L)
- H₂CO₃: **1.05-1.035 mmol/L**
- O₂ saturation: **94-100%**

COMMON SOURCES OF ERROR

| Error | pCO2 | рН | pO2 | Effect |
|---|----------|----------|--------------|-----------|
| Sample sitting at room temperature for more than 30 | 1 | 1 | \checkmark | Acidosis |
| mins | | | | |
| Bubbles in syringe, uncapped specimen | 1 | 1 | \uparrow | Alkalosis |
| Hyperventilation | | | | Alkalosis |
| Specimen exposed to air | | | | Alkalosis |

SAMPLE:

- 1. pH = 7.25, pCO₂ = 42 and HCO₃ = 16
 - ✓ determine acid-base status

AMINES

ENDOCRINOLOGY

• study of endocrine glands and the hormones they secrete

HORMONES

• are chemical signals that are secreted by cells into the blood stream that travels to its target tissues

POSITIVE FEEDBACK

An increase in the hormone product results to an elevated activity (another hormone production) of the system

NEGATIVE FEEDBACK

A decrease in the hormone product results to a decreased activity (another hormone production) of the system

CLASSIFICATION OF HORMONES

| CLASSIFICATION | EXAMPLE |
|-----------------------|--|
| PEPTIDES/POLYPEPTIDES | |
| Water soluble | |
| A. GLYCOPROTEIN | HCG, TSH, EPO, FSH |
| B. POLYPEPTIDES | ADH, GH, ACTH, Prolactin |
| STEROIDS | |
| • Synthesized from | Aldosterone, Estrogen, Cortisol, Progesterone, |
| cholesterol | Testosterone, Vitamin D |
| Insoluble | |

| GLAND | HORMONES | INFORMATION |
|---------------------|--------------|--|
| Hypothalamus | Releasing | TRH – regulates production of TSH and |
| | Hormones | prolactin |
| | | GnRH – regulates production of LH and FSH |
| | | GHRH – regulates production of GH |
| | | CRH – regulates production of ACTH |
| | Somatostatin | Inhibitor of GH and TSH production |
| | Dopamine | Prolactin release inhibitor |
| Anterior pituitary | GH | Most abundant pituitary hormone |
| | | Gigantism: increase (excess) in GH before |
| | | the closure of epiphyseal plate |
| | | Acromegaly: increase (excess) in GH after |
| | | the closure of epiphyseal plate |
| | | Dwarfism: a deficiency of GH |
| | Prolactin | Initiates and maintains lactation |
| | | Highest levels at 4am, 8am, 8pm and 10pm |
| | | Prolactinoma: most common type of |
| | | functional pituitary tumor |
| | TSH | Stimulation for the production of T3 and T4 |
| | LH | For secretion of progesterone; for ovulation |
| | ACTH | Stimulation for the production of |
| | | adrenocortical steroid formation and |
| | | secretion |
| | FSH | For secretion of estrogen |
| | | For development of seminiferous tubules; |
| | | spermatogenesis |
| Posterior pituitary | Oxytocin | Stimulates contraction of the uterine |
| ~ only releases | | "Fergusson reflex" |
| hormones (doesn't | | Also acts in parturition and in transport of |

Epinephrine, norepinephrine, T3, T4, melatonin

PROPERTY OF MEDTECH REVIEW NOTES24 | P a g e

| produce) | | sperm |
|-----------------------|------------------|--|
| | | Also, for milk ejection (suckling |
| | | asstimulator) |
| | ADH | Aka vasopressin |
| | | For water balance and blood pressure |
| | | elevation |
| | | Deficiency: diabetes insipidus |
| Thyroid gland | T3 and T4: | For metabolism |
| | produced by | There are more T4 than T3 |
| | follicular cells | T3 is more biologically active |
| | | Primary hyperthyroidism (Graves' disease) |
| | | ✓ increased T3 and T4 but decreased TSH |
| | | ✓ presence of anti-TSH receptor antibody |
| | | Secondary hyperthyroidism: both FT4 and |
| | | TSH are increased |
| | | Primary hypothyroidism (Hashimoto's |
| | | thyroiditis) |
| | | ✓ increased TSH but decreased T3 and |
| | | T4 |
| | | ✓ presence of anti-TPO antibody |
| | | Myxedema: manifestation of Hashimoto's |
| | | disease |
| | Calcitonin: | A calcium and phosphate regulator |
| | produced by | |
| | parafollicular | |
| | cells | |
| Parathyroid gland: | РТН | Produced and secreted by chief cells of |
| smallest gland in the | | parathyroid gland |
| body | | For bone resorption |

| | | Primary hyperparathyroidism: increased |
|---------------|-------------|--|
| | | ionized calcium |
| | | Secondary hyperparathyroidism: decreased |
| | | ionized calcium |
| Adrenal gland | Cortisol | Secreted by zona fasciculate |
| | | Highest levels in: 6am-9am |
| | | Lowest levels: 11pm-3am |
| | | Cushing's syndrome: increased levels of |
| | | cortisol and ACTH but decreased levels of |
| | | aldosterone and renin are notable |
| | | ✓ screening test: 24hr urine free |
| | | cortisol test |
| | | Confirmatory: low dose |
| | | dexamethasone suppression test and |
| | | CRH stimulation test |
| | | Cushing's disease: increased levels of ACTH |
| | | due to tumor on the pituitary gland |
| | | Methods: Porter-Silber reaction |
| | | (corticosteroids); + reaction = yellow |
| | | pigment |
| | | Zimmerman reaction (ketosteroids) + |
| | | reaction = reddish purple color |
| | Aldosterone | Secreted by zona glomerulosa |
| | | Most important mineralocorticoid |
| | | Responsible to Na+ and K+ retention |
| | | Barterr's syndrome: there is a defect in the |
| | | kidney's ability to reabsorb sodium |
| | | Conn's syndrome (1' hyperaldosteronism): |
| | | there is hypokalemia and hypernatremia |
| | | Liddle's syndrome: there is an excess |
| | | sodium reabsorption and excretion of |
| | | potassium due to defect in the DCT |

PROPERTY OF MEDTECH REVIEW NOTES25 | P a g e

| | Catecholamines | Secreted in medulla |
|---------------------|----------------|--|
| | | 80% epinephrine, 20% norepinephrine |
| | | Pheochromocytoma: tumor that results to |
| | | overproduction of catecholamines |
| Reproductive glands | Testosterone | Principal androgen in the blood |
| | | Most potent male androgen |
| | | Synthesized by the Leydig cells |
| | Estrogen | Estrone: most abundant in menopausal |
| | | women |
| | | Estradiol: most potent; most abundant in |
| | | pre-menopausal women |
| | | Estriol: major estrogen detected during |
| | | pregnancy; produced by placenta; marker |
| | | for down syndrome |
| | | Kober reaction: used to analyze estrogens |
| | Progesterone | Single best hormone to evaluate if ovulation |
| | | has occurred |
| Pancreas | Insulin | Hypoglycemic agent |
| | Glucagon | Hyperglycemic agent |

METABOLITES OF HORMONES!

- Dopamine: Homovanilic acid
- Serotonin: 5-HIAA
- Epinephrine: Vanillyl mandelic acid and metanephrine
- Norepinephrine:
 - ✓ Urine: 3-methoxy-4-hydroxyphenylglycol
 - ✓ Blood: vanillyl mandelic acid

TOXICOLOGY

TOXIC AGENTS

- Alcohol
 - ✓ Ethanol (grain alcohol): most commonly abused chemical substance

| STAGES OF IMPAIRMENT | | | |
|---|--|--|--|
| BLOOD ALCOHOL (% w/v) | SIGNS AND SYMPTOMS | | |
| 0.01 – 0. 05 | No obvious impairment, some changes observable on | | |
| | performance testing | | |
| 0.03 - 0.12 | Mild euphoria, decreased inhibitions, some impairment | | |
| | of motor skills | | |
| 0.09 – 0.25 | Decreased inhibitions, loss of critical judgment, memory | | |
| | impairment, diminished reaction time | | |
| 0.18 - 0.30 | Mental confusion, dizziness, strongly impaired motor | | |
| | skills (staggering, slurred speech) | | |
| 0.27 – 0.40 | Unable to stand or walk, vomiting, impaired | | |
| | consciousness | | |
| 0.35 – 0.50 | Coma and possible death | | |
| >0.10 – PRESUMPTIVE EVIDENCE OF DRIVING UNDER ALCOHOL INFLUENCE | | | |

- Cyanide
 - ✓ Odor of bitter almonds
- Arsenic
 - ✓ Odor of garlic; keratinophilic
- Carbon monoxide
 - ✓ Odorless, colorless and tasteless gas
 - ✓ Binds to hemoglobin 250 times (in terms of affinity) as compared to oxygen
 - ✓ Makes blood cherry-red in color

• Mercury

✓ Nephrotoxic and can bind myelin (in neurons)

- Lead
 - ✓ Specimen of choice: whole blood
 - ✓ Inhibits enzymes D-ALA synthetase & pyrimidine-5'-nucleotidase
- Organophosphates
 - ✓ Found in insecticides and pesticides
 - ✓ Hepatotoxic
 - ✓ Can inhibit enzyme acetylcholinesterase

| DRUGS OF ABUSE | | | |
|-----------------|----------------------|--|--|
| DRUG METABOLITE | | | |
| Amitriptyline | Nortryltyline | | |
| Cocaine | Benzoylecgonine | | |
| Heroin | Morphine | | |
| Marijuana | Tetrahydrocannabinol | | |
| Primodine | Phenobarbital | | |
| Procainamide | NAPA | | |

TOXIC DRUG MONITORING

DEFINITION OF TERMS:

- Pharmacodynamics: what the drugs do to the body
- Pharmacokinetics: what the body does to the drug (biotransformation, distribution, metabolism and elimination)
- First pass metabolism: drugs enter the hepatic route first before entering the general circulation
- Half-life: time needed for a drug's concentration in serum to decrease into half
- Peak specimen: collection of this is done 30-60 mins after the administration of drug
- Trough specimen: this is collected **before** administration of the succeeding dose

| CLASSIFICATION OF DRUGS | REPRESENTATIVE DRUGS |
|------------------------------|---|
| Antibiotics | Aminoglycosides, chloramphenicol, vancomycin |
| Anticonvulsants | Ethosuximide, Carbamazepine, Phenytoin, Phenobarbital, |
| | Valproic acid |
| Antidepressants | Lithium, Fluoxetine and tricyclic antidepressants |
| Anti-inflammatory/analgesics | Aspirin, acetaminophen |
| Anti-neoplastic | Busulfan, methotrexate |
| Bronchodilators | Theohylline |
| Cardioactive | Digoxin, Procainamide, Lidocaine, Propanolol, Quinidine |
| Immunosuppressives | Tacrolimus (FK-506), Prednisone, Cyclosporine |
| GOOD TO KNOW FOR THE DRU | JGS: |

- - $\checkmark~$ Aspirin: drug that inhibits ${\bf cyclooxygenase}$
 - ✓ Acetaminophen: hepatotoxic drug
 - \checkmark Lithium: for treatment of bipolar disorder or manic depression

- ✓ Phenobarbital: used for treatment of grand-mal
- ✓ Valproic acid: for treatment of petit mal
- ✓ Vancomycin: cause of **red man syndrome**

CONVERSION FACTORS

| (derived from Clinical Chemistry Handbook of Dean Maria Teresa T. Rodriguez, RMT, MAEd, MSMT) | | |
|--|--------------------------------|----------------------|
| ANALYTES | CONVENTIONAL UNITS TO SI UNITS | CONVERSION FACTOR |
| ALBUMIN | g/dL to g/L | 10 |
| PHOSPHOLIPID | | 0.01 |
| TOTAL PROTEIN | | 10 |
| AMMONIA | μg/dL to μmol/L | 0.587 |
| THYROXINE | μg/dL to nmol/L | 12.9 |
| BICARBONATE | mEq/L to mmol/L | 1.0 |
| CHLORIDE | | 1.0 |
| MAGNESIUM | | 0.5 |
| POTASSIUM | | 1.0 |
| SODIUM | | 1.0 |
| LITHIUM | mEq/L to μmol/L | 1.0 |
| BUN | mg/dL to mmol/L | 0.357 |
| CALCIUM | | 0.25 |
| CHOLESTEROL | | 0.026 |
| GLUCOSE | | 0.0555 |
| PHOSPHORUS | | 0.323 |
| TRIGLYCERIDE | | 0.0113 |
| URIC ACID | | 0.0595 |
| BILIRUBIN | mg/dL to μmol/L | 17.1 |
| CREATININE | | 88.4 |
| IRON | | 0.179 |
| pCO ₂ | mm/Hg to kPa | 0.133 |

PROPERTY OF MEDTECH REVIEW NOTES28 | P a g e

pO₂

0.133

REFERENCES:

Henry's Clinical Diagnosis and Management by Laboratory Methods

Clinical Chemistry: Principles, Procedures and Correlations by Michael Bishop

Clinical Chemistry Review Handbook for Medical Technologists by Dean Maria Teresa T. Rodriguez, RMT, MAEd, MSMT

Clinical Chemistry Notes of Mr. Errol E. Coderes RMT, IMLT, MLS (ASCPi)^{CM}

Clinical Chemistry Checkpoint notes of Ms. Judea Marie Policarpio, RMT

Intensive Review Notes of University of the Immaculate Conception – Medical Laboratory Science Program

PROPERTY OF MEDTECH REVIEW NOTES30 | P a g e